LightPath Divests China Ops, Completes Western Manufacturing Shift

What happened

LightPath Technologies announced it has signed a definitive agreement to sell its China subsidiary, completing its transition to a fully Western-aligned manufacturing footprint. The divestiture involves LightPath (Zhenjiang) Optical Instrumentation Co., Ltd., which contributed only about $2.9 million in FY25 revenue, less than 8% of total. Management frames this as reinforcing the company's position as a trusted supplier for mission-critical defense and commercial applications, likely resonating with U.S. customers concerned about supply chain security. However, given the small revenue contribution, this move does not materially alter the financial profile or the significant execution risks facing the core G5 infrared camera business. The divestiture reduces geographic complexity but does not address the fundamental challenge of converting a ~$90 million backlog into sustainable profitability and positive cash flow.

Implication

The sale of the China operations simplifies LightPath's corporate structure and removes a minor geopolitical overhang, which may marginally lower risk perception. However, the China subsidiary generated just $2.9 million in FY25 revenue with no disclosed profits, so the financial impact of the divestiture is negligible. The core thesis remains unchanged: LightPath is a high-growth but unprofitable defense optics company trading at elevated multiples relative to its track record. The company still needs to demonstrate that its backlog-driven revenue growth can translate into gross margins above 30% and positive free cash flow, which the report's bear case doubts will happen. Until concrete margin improvement and cash generation are evident, the stock remains overvalued and presents poor risk-reward for new investors.

Thesis delta

The divestiture of China operations does not alter the fundamental investment thesis. The move is strategically sound but has minimal financial impact, and the company still faces the same margin and cash flow challenges that underpin the Strong Sell rating. No change to the bearish outlook; the stock remains overvalued relative to its earnings and cash flow trajectory.